{"filing":{"accession_number":"0001477932-26-003740","cik":"0000093314","ticker":"VNRX","company_name":"VOLITIONRX LTD","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"vnrx_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/93314/000147793226003740/vnrx_8k.htm"},"events":[{"id":6007,"run_id":5272,"accession_number":"0001477932-26-003740","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"VolitionRx entered into a securities purchase agreement on June 7, 2026, to sell 2,960,000 shares of common stock and 1,480,000 common stock purchase warrants at $1.55 per unit, raising approximately $4.1 million in net proceeds with additional dilutive potential from warrant exercises.","company_name":"VOLITIONRX LTD","ticker":"VNRX","filing_date":"2026-06-09","form":"8-K","submitted_at":null,"items":[{"id":5678,"accession_number":"0001477932-26-003740","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"VolitionRx entered into a securities purchase agreement on June 7, 2026, to sell 2,960,000 shares of common stock and 1,480,000 common stock purchase warrants at a combined price of $1.55 per unit, raising approximately $4.1 million in net proceeds. This is a registered public offering of equity securities with significant dilutive potential (warrants exercisable for an additional $2.3 million in gross proceeds), representing a material capital raise for a small-cap biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:03:34.108601+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5679,"accession_number":"0001477932-26-003740","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces pricing of an offering via press release dated June 7, 2026. While the Item 8.01 section does not specify the offering type, the reference to \"the Offering\" and its pricing announcement is consistent with a capital raise. For a small-cap biotech company like VolitionRx, an equity offering announcement typically signals a dilutive issuance material to shareholders. The press release (Exhibit 99.1) would contain the specific terms, but the pricing announcement itself is the reportable event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:03:34.108601+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5678,"accession_number":"0001477932-26-003740","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"VolitionRx entered into a securities purchase agreement on June 7, 2026, to sell 2,960,000 shares of common stock and 1,480,000 common stock purchase warrants at a combined price of $1.55 per unit, raising approximately $4.1 million in net proceeds. This is a registered public offering of equity securities with significant dilutive potential (warrants exercisable for an additional $2.3 million in gross proceeds), representing a material capital raise for a small-cap biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:03:34.108601+00:00","company_name":"VOLITIONRX LTD","ticker":"VNRX","filing_date":"2026-06-09"},{"id":5679,"accession_number":"0001477932-26-003740","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces pricing of an offering via press release dated June 7, 2026. While the Item 8.01 section does not specify the offering type, the reference to \"the Offering\" and its pricing announcement is consistent with a capital raise. For a small-cap biotech company like VolitionRx, an equity offering announcement typically signals a dilutive issuance material to shareholders. The press release (Exhibit 99.1) would contain the specific terms, but the pricing announcement itself is the reportable event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:03:34.108601+00:00","company_name":"VOLITIONRX LTD","ticker":"VNRX","filing_date":"2026-06-09"}]}